The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.
about
Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)Fluoroquinolones for treating tuberculosisComparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complexComparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complexCorrelation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteriaFluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistanceComparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacinOfloxacin/beta-cyclodextrin complexation.Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpAGenetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosisTuberculosis: 9. Treatment.Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combinationPharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patientsEfflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteriaSuccessful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort studyIntegrating fluoroquinolones into the hospital formulary.Peritonitis due to Mycobacterium fortuitum following gastric banding.Fluoroquinolones and tuberculosis.Type II pneumocytes in the evaluation of drug antimycobacterial activity.Inhibitory effect of NO-releasing ciprofloxacin (NCX 976) on Mycobacterium tuberculosis survivalWhich agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?Emerging aspects of Buruli ulcer.Update on antimicrobial agents: new indications of older agents.Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Treatment of spondylodiscitisMedicinal potential of ciprofloxacin and its derivatives.In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans.Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones.Cardiac device infections due to Mycobacterium fortuitum.Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery.[Pyogenic spondylodiscitis: therapy algorithm and a new classification for therapeutic decision-making].Disseminated Mycobacterium avium infection in young cats: overrepresentation of Abyssinian cats.
P2860
Q24202081-330D1507-2618-4E76-BD00-4458AA3B274CQ24242773-457ACA04-3FA8-4A5D-9F70-F5724C4BEE2CQ28343759-C7F55163-E7C0-429A-BBAB-7D0F964ED853Q28343858-E04FE8BA-7E4B-4542-B4CC-A7F258BB6ECCQ28368322-CA0AF2FF-F9FD-48D7-BE23-F2DC48862DB5Q28369156-62F340D2-A8B6-4480-9EA8-96BED8F069BDQ28376027-F0F38F84-947E-4C22-B9D2-03351F9F5703Q30660348-C149919B-6AD7-472C-9D4B-9BE78A87BD53Q32035273-C2DC7F47-E941-4A56-B42E-CD1763C4E2BBQ33630442-BC9E4B51-33BE-4011-9C95-AFC975EF39C6Q33729210-51EB9861-CF03-44DE-9ED9-718259C6A3ADQ33836497-BDE79D31-E172-4737-996A-CF253519B6E1Q33977737-87CC9A4D-663C-4807-978F-11B0ADF566C8Q34035762-47B1E423-E39A-4399-8D68-39411EEADD2EQ34137837-2CC7CCC0-2577-46AE-A133-8B1370753D78Q34408454-8A8A68C0-FC9A-4CB2-8E1F-1EAFFE726822Q34468988-80EE12A2-5562-4890-923F-99E343AB6483Q34519143-178B778F-E4EA-44C2-B2F3-72A7B6F861E3Q35058087-88EA9AF9-DA3A-4EFA-BC34-F86E4ADE6D78Q35102614-63B6A48B-B1F6-42ED-809E-B8ECE3BE5D6AQ35849799-51851F09-AAF7-4C85-83FF-48E5FEEEF19CQ35917186-22E55A63-72A7-42A4-9977-AB2DBA7EC36AQ36222046-8BF571B2-CF0F-4E7D-960F-73E016987080Q37032794-61FB8756-2520-4CDD-B1EC-B396400B25BEQ37346929-3902F9CD-1553-4E6A-B0AA-49FE11000461Q37964972-16729539-1D51-401B-BE40-D101DB0F7E8FQ38068970-5FCC4E64-DC08-4599-AB53-FF920B53343EQ38886251-E2606B51-6E96-41FE-9EAA-A0AE8AD805CDQ40348437-5CEE951E-F4AF-4FC1-986F-3798C9FBE6CBQ40670499-32994DCD-8260-4770-9F3E-67C353167852Q42961541-F3500D7A-BA7C-4AF8-843A-91864A0FBCE0Q43658062-BCE1713D-BB23-40A8-BCC8-A403DE2E0444Q46754410-6B0D7F9C-10C0-4A27-916E-34622323D4B0
P2860
The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.
@en
type
label
The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.
@en
prefLabel
The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.
@en
P356
P1476
The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.
@en
P2093
Alangaden GJ
P304
P356
10.1086/516116
P407
P577
1997-11-01T00:00:00Z